SCHEMBL25370790

SCHEMBL25370790

Cc1nc(C(F)(F)F)ccc1S(=O)(=O)N1CC2(CN([C@H](C)C3CCOCC3)C2)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 1/20 0.39
▸ KCNH2 Q12809 1/20 0.38
▸ PSEN1 P49768 1/20 0.33
▸ PSEN2 P49810 1/20 0.33
▸ APH1B Q8WW43 1/20 0.33
▸ NCSTN Q92542 1/20 0.33
▸ APH1A Q96BI3 1/20 0.33
▸ PSENEN Q9NZ42 1/20 0.33
▸ BRS3 P32247 6/20 0.33
▸ PTGS2 P35354 2/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ CNR1 P21554 1/20 0.31
▸ PTGS1 P23219 1/20 0.31
▸ CASP3 P42574 1/20 0.31
▸ NR1I2 O75469 2/20 0.31
▸ BRD4 O60885 1/20 0.31
▸ BAZ2A Q9UIF9 1/20 0.31
▸ PDE5A O76074 1/20 0.30
▸ FPR1 P21462 1/20 0.30
▸ FEN1 P39748 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25372346 1.00 TRPV4 (0.39) TRPV4KCNH2PSEN1PSEN2APH1B
SCHEMBL25370786 1.00 TRPV4 (0.39) TRPV4KCNH2PSEN1PSEN2APH1B
SCHEMBL25371470 0.94 KCNH2 (0.36) TRPV4KCNH2PSEN1PSEN2APH1B
SCHEMBL25371474 0.94 KCNH2 (0.36) TRPV4KCNH2PSEN1PSEN2APH1B
SCHEMBL25369985 0.90 TRPV4 (0.40) TRPV4BRS3NR1I2
SCHEMBL25369988 0.90 TRPV4 (0.40) TRPV4BRS3NR1I2
SCHEMBL25372466 0.90 TRPV4 (0.40) TRPV4BRS3NR1I2
SCHEMBL25370983 0.89 TRPV4 (0.33) TRPV4KCNH2FPR1
SCHEMBL25370985 0.89 TRPV4 (0.33) TRPV4KCNH2FPR1
SCHEMBL25370988 0.89 TRPV4 (0.33) TRPV4KCNH2FPR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171463-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. 2025-05-29 — — US claimed
EP-4482587-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-01-01 — — EP claimed
WO-2023164063-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2023-08-31 — — WO claimed
US-20250171463-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. 2025-05-29 — — US disclosed
EP-4482587-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-01-01 — — EP disclosed
WO-2023164063-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2023-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171463-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF EBPL, EBP, CREBBP TRPV4 4535/4885KCNH2 4874/4885PSEN1 1794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback